5-AMINO 1 MQ -10mg

5-AMINO 1 MQ -10mg

CAS (Pre-validation): N/A (form dependent)

Chemical Formula (Pre-validation): Quinolinium derivative

Molecular Weight (Pre-validation): ≈159–286 g/mol

- +
5-Amino-1MQ
Scientific Overview, Mechanism, Clinical Use and Evidence
 
Scientific Overview
 
5-Amino-1MQ is an investigational NNMT (nicotinamide N-methyltransferase) inhibitor studied in metabolic research. NNMT dysregulation has been linked to obesity, insulin resistance, and altered NAD+ metabolism. In metabolic medicine frameworks, modulation of NNMT is explored as a strategy to improve adipocyte energy handling and metabolic flexibility.
Mechanism of Action
 
NNMT inhibition may:
 
•  Increase intracellular NAD+ availability
•  Reduce methyl donor depletion
•  Improve adipocyte mitochondrial efficiency
•  Shift cellular metabolism toward enhanced oxidative utilization
Biological and Clinical Effects
 
Preclinical research suggests:
 
•  Reduced adiposity
•  Improved glucose tolerance
•  Enhanced mitochondrial function in adipose tissue
 
Human clinical evidence remains limited and exploratory.
Time of Use / Treatment Duration
 
•  Exploratory metabolic protocols: 4–6 weeks
•  Reassessment after initial cycle recommended
•  Long-term continuous use not supported by robust human safety data
 
Use should remain limited to controlled or physician-supervised settings.
Safety, Tolerability, and Precautions
 
Human safety data are still evolving. Conservative implementation and monitoring are recommended.
Detailed References
Kraus D, et al. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495):258–262.
 
Kannt A, et al. (2015). NNMT as a metabolic regulator in obesity and type 2 diabetes. Pharmacology & Therapeutics, 146:82–92.
 
Hong S, et al. (2015). NNMT regulates cellular methylation potential and metabolic reprogramming in adipocytes. Molecular Metabolism, 4(10):795–807.
 
Neelakantan H, et al. (2018). Selective NNMT inhibitors reverse obesity in preclinical models. Biochemical Pharmacology, 156:38–50.
 
LaValle J. The Complete Guide to Peptides. Discussion on NAD+ modulation and metabolic flexibility strategies.
5-Amino-1MQ RegenPept
Posology (Clinical Practice–Oriented)
Human dosing protocols are not standardized in approved clinical frameworks.
In investigational or experimental contexts:
•  Reported oral ranges in research settings: 25–100 mg daily
•  Divided dosing (BID) has been described
•  Duration typically limited to short research cycles
Strict medical supervision is required.
Clinical Practice Framing for Nootropics & Focus
Within metabolic optimization frameworks, 5-Amino-1MQ is positioned cautiously as an experimental metabolic regulator and should not be considered first-line therapy.
The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.
Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.
RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.
Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.
Quantity

10 vials, unit

Reviews

There are no reviews yet.

Be the first to review “5-AMINO 1 MQ -10mg”

Your email address will not be published. Required fields are marked *

Related products

plugins premium WordPress
Scroll to Top